Luveltamab tazevibulin,Pegfilgrastim
Sutro Biopharma,Amgen
['pivotal study', 'pivot,io,i', 'ovarian', '$stro', 'sutro']
sutro biopharma announces oral presentation at 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal study reframe-o1. fore more info, #asco23 $stro 
Sutro Biopharma, Inc. is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineer